Company Announces GR86 Yuzu Edition for 2026GR86 Yuzu Edition Features Exclusive Yuzu Yellow Exterior Color, Black Wheels and a Performance Package2.4-Liter, 4-Cylinder Boxer Engine Generates 228 Horsepower and 184 lb.-ft. of TorqueComplimentary 1-year membership to the National Auto Sport AssociationExpected to arrive at Dealerships Fall 2025LONG BEACH, Calif., April 3, 2025 /PRNewswire/ -- For 2026, the Toyota sports car lineup is getting brighter with the GR86 Yuzu Edition. This vibrant exterior color is a nod to a memorable special edition of GR86's predecessor, the Scion FR-S Release Series 1.0.

Toyota Introduces GR Supra MkV Final Edition at Grand Prix of Long BeachMkV Final Edition Features Optimized Tuning, Improved Braking and Chassis and Suspension Updates3.0 and 3.0 Premium Grades AvailableAll Grades Offer 382 Horsepower with 368 lb-ft. of TorqueLONG BEACH, Calif., April 3, 2025 /PRNewswire/ -- Born on the track, the GR Supra is a testament to Toyota's commitment to motorsports-bred vehicle development, blending engineering excellence, innovation, and lessons learned from the most demanding conditions that only racing can provide. For the 2026 model year, Toyota celebrates this legendary sports car with the GR Supra MkV Final Edition.

Available to consumers around the world sending money to their loved ones in Myanmar via WesternUnion.com and the Western Union app In response to the devastating earthquake that recently struck Myanmar, Western Union today announced that it is offering consumers around the world zero-fee international money transfers1 to the country. Effective immediately until midnight, 00:00 Myanmar Standard Time on 10 April 2025, individuals can send funds to Myanmar via WesternUnion.com or the Western Union mobile app, ensuring families can provide crucial support to their loved ones during this time of urgent need. Western Union remains committed to providing support during times of crisis, offering

Citigroup Declares Preferred Dividends The Board of Directors of Citigroup Inc. today declared a quarterly dividend on Citigroup's common stock of $0.56 per share, payable on May 23, 2025, to stockholders of record on May 5, 2025. The Board of Directors of Citigroup Inc. also declared dividends on Citigroup's preferred stock as follows: –5.950% Fixed Rate/Floating Rate Noncumulative Preferred Stock, Series P, payable May 15, 2025, to holders of record on May 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $29.75 for each receipt held. – 4.000% Fixed Rate Reset Noncumulative Preferred Stock, Series W, payable June 10, 20

BofA Securities downgraded RH from Buy to Underperform and set a new price target of $130.00 from $410.00 previously

CapitalOne upgraded Caesars Entertainment from Equal Weight to Overweight and set a new price target of $47.00 from $51.00 previously

HSBC Securities downgraded NVIDIA from Buy to Hold and set a new price target of $120.00

BofA Securities downgraded RxSight from Buy to Underperform and set a new price target of $22.00 from $36.00 previously

4 - BioCardia, Inc. (0000925741) (Issuer)

4 - DOLLAR TREE, INC. (0000935703) (Issuer)

4 - SmartStop Self Storage REIT, Inc. (0001585389) (Issuer)

4 - SmartStop Self Storage REIT, Inc. (0001585389) (Issuer)

4 - S&T BANCORP INC (0000719220) (Issuer)

4 - S&T BANCORP INC (0000719220) (Issuer)

4 - Amalgamated Financial Corp. (0001823608) (Issuer)

4 - J.Jill, Inc. (0001687932) (Issuer)

SCHEDULE 13G/A - Logan Ridge Finance Corp. (0001571329) (Subject)

SCHEDULE 13D/A - CMB.TECH NV (0001604481) (Filed by)

SCHEDULE 13D/A - Victory Capital Holdings, Inc. (0001570827) (Subject)

SCHEDULE 13G - Playa Hotels & Resorts N.V. (0001692412) (Subject)

For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

For Immediate Release: February 21, 2025 Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very rare lipid storage disease.“The FDA is dedicated to supporting new drug development for rare diseases including very rare metabolic diseases like cerebrotendinous xanthomato

Company Announces GR86 Yuzu Edition for 2026GR86 Yuzu Edition Features Exclusive Yuzu Yellow Exterior Color, Black Wheels and a Performance Package2.4-Liter, 4-Cylinder Boxer Engine Generates 228 Horsepower and 184 lb.-ft. of TorqueComplimentary 1-year membership to the National Auto Sport AssociationExpected to arrive at Dealerships Fall 2025LONG BEACH, Calif., April 3, 2025 /PRNewswire/ -- For 2026, the Toyota sports car lineup is getting brighter with the GR86 Yuzu Edition. This vibrant exterior color is a nod to a memorable special edition of GR86's predecessor, the Scion FR-S Release Series 1.0.

MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Robert A. DeMichiei to its board of directors. A seasoned leader with over 30 years of experience in financial strategy, healthcare operations, and board governance, Mr. DeMichiei served as executive vice president and chief financial officer at the University of Pittsburgh Medical Center (UPMC) from 2004 to 2020. During his tenure, he played a pivotal role in driving UPMC's financial growth and led numerous strategic initiatives, including mergers and acquisitions, supply chain management, and revenue cycle improvements. Prior to joining U

Signals Next Step in Transforming Go-to-Market Growth Initiatives in Data Management for the AI Era Appoints John Fichthorn to the Board and Lewis Moorehead as Chief Financial Officer Quantum Corporation (NASDAQ:QMCO) ("Quantum" or the "Company"), a leader in solutions for AI and unstructured data, today announced several strategic developments to provide financial and operational flexibility, facilitate growth initiatives, and better serve the evolving data needs of today's AI-driven organizations. Dialectic Capital Management, an investment management firm, has purchased all of Quantum's $51 million of outstanding term debt previously held by Blue Torch Capital. With this transfer, John

Citigroup Declares Preferred Dividends The Board of Directors of Citigroup Inc. today declared a quarterly dividend on Citigroup's common stock of $0.56 per share, payable on May 23, 2025, to stockholders of record on May 5, 2025. The Board of Directors of Citigroup Inc. also declared dividends on Citigroup's preferred stock as follows: –5.950% Fixed Rate/Floating Rate Noncumulative Preferred Stock, Series P, payable May 15, 2025, to holders of record on May 5, 2025. Holders of depositary receipts, each representing one-twenty-fifth of a full preferred share, will be paid $29.75 for each receipt held. – 4.000% Fixed Rate Reset Noncumulative Preferred Stock, Series W, payable June 10, 20

Douglas Emmett, Inc. (NYSE:DEI), a real estate investment trust (REIT), announced today that it plans to release its 2025 first quarter earnings results after market close on Tuesday, May 6, 2025. A live conference call is scheduled for the following day, Wednesday, May 7, 2025, at 11:00 a.m. Pacific Time / 2:00 p.m. Eastern Time. Jordan Kaplan, President and Chief Executive Officer, will host the call along with Peter Seymour, Chief Financial Officer, Kevin Crummy, Chief Investment Officer, and Stuart McElhinney, Vice President Investor Relations. Interested parties can listen to the call via the following: INTERNET: Go to www.douglasemmett.com/investors at least fifteen minutes prior to

In conjunction with Helmerich & Payne, Inc.'s (NYSE:HP) fiscal second quarter 2025 earnings release, you are invited to listen to its conference call on Thursday, May 8, 2025, at 11:00 a.m. (ET) with John Lindsay, President and CEO, Kevin Vann, Senior Vice President and CFO, and Dave Wilson, Vice President of Investor Relations. The earnings release and presentation for the quarterly results will be available on the company's website at hpinc.com. Investors may listen to the conference call either by phone or audio webcast.   What: Helmerich & Payne, Inc.'s Fiscal Second Quarter 2025 Earnings Release. Other material developments may also be discussed.         Whe

DALLAS, April 03, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ:TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the first quarter of 2025 before market on Thursday, April 17, 2025. Executive management will host a conference call and webcast to discuss first quarter 2025 operating results on Thursday, April 17, 2025, at 9:00 a.m. EDT. Participants may pre-register for the call by visiting https://www.netroadshow.com/events/login?show=c5d392d2&confId=80603 and will receive a unique PIN number to be used when dialing in for the call for immediate access. Alternatively, participants may call 833.470.1428 a

SC 13D/A - ALLIANCEBERNSTEIN HOLDING L.P. (0000825313) (Subject)

SC 13D/A - CVR ENERGY INC (0001376139) (Subject)

SC 13D/A - INCOME OPPORTUNITY REALTY INVESTORS INC /TX/ (0000949961) (Subject)

SC 13D/A - Arcus Biosciences, Inc. (0001724521) (Subject)

Recently, on July 4, 2024, a significant insider purchase was recorded at Allied Gaming & Entertainment Inc. as Large owner Choi Roy bought $456,750 worth of shares (360,000 units at $1.27), increasing direct ownership by 14% to 2,871,822 units (SEC Form 4). This purchase is notable for the size of the transaction and the percentage increase in direct ownership, indicating a strong belief in the company's future prospects. Insider purchases are generally viewed positively by investors as they signal confidence from those with intimate knowledge of the company's operations. Examining other recent insider transactions at Allied Gaming & Entertainment Inc., we notice a few patterns worth explo

Recently, on June 25, 2024, Director Romano Kelly A bought $100,051 worth of shares in Athira Pharma Inc. This transaction involved acquiring 42,400 units at $2.36 per share, resulting in a significant increase in direct ownership by 111% to 80,715 units. The purchase was disclosed in the SEC Form 4 filing. Insider buying is often considered a bullish signal as insiders may have insights into the company's future performance. It's essential to analyze this insider purchase in conjunction with previous insider transactions to identify any patterns or trends. Taking into account the information from the SEC filings, several other insiders at Athira Pharma Inc. have also been active in the sto

Recently, on June 26, 2024, Director Juda Scott bought $36,350 worth of shares (5,000 units at $7.27) (SEC Form 4) in INmune Bio Inc. This insider purchase is significant as it indicates confidence from someone within the company towards its future growth prospects. It's interesting to note that this purchase by Juda Scott follows a series of transactions by other insiders in the company. For example, Moss David J bought $149,993 worth of shares (18,028 units at $8.32) on April 24, 2024, increasing direct ownership by 1% to 1,268,179 units. This demonstrates a consistent trend of insider buying within the organization. Looking back at previous transactions, on May 16, 2024, several key ins

Monopar Therapeutics Inc. has recently seen notable insider activity, with Chief Operating Officer Cittadine Andrew purchasing $25,574 worth of shares on June 21st, 2024. This purchase, comprising 32,508 units at $0.79, increased Cittadine's direct ownership by 21% to 186,132 units as reported in the SEC Form 4. When analyzing this transaction alongside other recent insider activities within the company, interesting patterns and trends start to emerge. Looking back, Cittadine Andrew has been consistently adding to his position in Monopar Therapeutics Inc. over the past few months, showcasing a strong conviction in the company's future prospects. On May 31st, Cittadine Andrew made a substan